Search sector opportunities

£2.1 million is available to support UK bioscience researchers and businesses in accessing and benefiting from access to STFC skills, expertise, capabilities and world-class facilities.

The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines, with robust research plans and potential for successful research development.

The Opportunities in STEM campaign in partnership with Mediaplanet will be launching on June 19 in the New Scientist magazine ahead of International Women in Engineering Day. 

Apply for UKRI’s Future Leaders Fellowships (Round 10) to secure funding for ambitious, independent research or innovation projects—open to early career researchers and innovators from eligible academic or non-academic institutions, with projects lasting up to four years and no cost limits.

Help shape the future of biopharma innovation by taking this 10-minute survey on biopharma entrepreneurship ecosystems and the support start-ups receive globally.

LifeArc's newly launched B-SMArT antibody discovery platform offers collaborators a clinically validated transgenic mouse model (Kymab/Sanofi) and advanced single B-cell selection technologies (Beacon and FACS) to generate fully human antibodies ready for in vivo testing.

This nationwide initiative is calling on companies, teams, and individuals to commit to a fitness challenge while raising vital funds for translational cancer research—helping life-saving innovations move from the lab to patients faster.

Cancer Research Horizon’s Seed Fund builds on 25 years of creating and building successful start-ups. It is a £15 million investment commitment from Cancer Research UK, managed by its dedicated Ventures team, to help bridge one of the most challenging stages of start-up creation: attracting early-stage risk capital.

The Functional Genomics Screening Laboratory – a joint venture between the Milner Therapeutics Institute, University of Cambridge, the Medical Research Council (MRC) and AstraZeneca – aims to combine know-how and experience to accelerate the development of biomarkers and therapeutics for diseases through functional interrogation of the genome at scale.